vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-608Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESЭффективность и безопасность тоцилизумаба у больных тяжелым системным ювенильным идиопатическим артритомTOCILIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH SEVERE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITISАлексееваЕ.А.AlexeevaE.I.neonatepearl@yandex.ruДенисоваР.В.DenisovaR.V.neonatepearl@yandex.ruВалиеваС.И.ValievaS.I.neonatepearl@yandex.ruБзароваТ.М.BzarovaT.M.neonatepearl@yandex.ruИсаеваК.Б.IsaevaK.B.neonatepearl@yandex.ruЧистяковаЕ.Г.ChistyakovaE.G.neonatepearl@yandex.ruСлепцоваТ.В.SleptsovaT.V.neonatepearl@yandex.ruМитенкоЕ.В.MitenkoE.V.neonatepearl@yandex.ruНаучный центр здоровья детей РАМН, Москва
Первый Московский государственный медицинский университет им. И.М. СеченоваScientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow
I.M. Sechenov First Moscow State Medical UniversityНаучный центр здоровья детей РАМН, МоскваScientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowНаучный центр здоровья детей РАМН, МоскваScientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow
I.M. Sechenov First Moscow State Medical University201116052011103Вопросы современной педиатрии24–32Copyright © Алексеева Е., Денисова Р., Валиева С., Бзарова Т., Исаева К., Чистякова Е., Слепцова Т., Митенко Е., 20112011Алексеева Е., Денисова Р., Валиева С., Бзарова Т., Исаева К., Чистякова Е., Слепцова Т., Митенко Е.Alexeeva E., Denisova R., Valieva S., Bzarova T., Isaeva K., Chistyakova E., Sleptsova T., Mitenko E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/608ReferencesCassidy J.T., Petty R.E. Juvenile idiopathic arthritis. In: Textbook of pediatric rheumatology. Eds. Cassidy J.T., Petty R.E. 5th ed. Philadelphia: WB Saunders. 2005.Cassidy J.T., Petty R.E. Juvenile idiopathic arthritis. In: Textbook of pediatric rheumatology. Eds. Cassidy J.T., Petty R.E. 5th ed. Philadelphia: WB Saunders. 2005.Алексеева Е.И., Валиева С.И., Бзарова Т.М.. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2009; 8(5):14–25.Алексеева Е.И., Валиева С.И., Бзарова Т.М.. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2009; 8(5):14–25.Алексеева Е. И., Литвицкий П. Ф. Руководство для врачей. Под общей ред. А.А. Баранова. М. 2007. 368 с.Алексеева Е. И., Литвицкий П. Ф. Руководство для врачей. Под общей ред. А.А. Баранова. М. 2007. 368 с.Veldhuis G.J., Willemse PH.B., Sleijfer D.T. et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non–small cell lung cancer. J. Clin. Oncol. 1995; 13: 2585–2593.Veldhuis G.J., Willemse PH.B., Sleijfer D.T. et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non–small cell lung cancer. J. Clin. Oncol. 1995; 13: 2585–2593.Rothwell N.J., Busbridge N.J., Lefeuvre R.A. et al. Interleukin–6 is a centrally acting endogenous pyrogen in the rat. Can. J. Physiol. Pharmacol. 1991; 69: 1465–1469.Rothwell N.J., Busbridge N.J., Lefeuvre R.A. et al. Interleukin–6 is a centrally acting endogenous pyrogen in the rat. Can. J. Physiol. Pharmacol. 1991; 69: 1465–1469.Castell J.V., Gomez-Lechon M.J., David M. et al. Recombinant human interleukin–6 (IL–6/BSF–2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 1988; 232: 347–350.Castell J.V., Gomez-Lechon M.J., David M. et al. Recombinant human interleukin–6 (IL–6/BSF–2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 1988; 232: 347–350.Nemeth E., Rivera S., Gabayan V. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 2004; 113: 1271–1276.Nemeth E., Rivera S., Gabayan V. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 2004; 113: 1271–1276.Ikebuchi K., Wong G.G., Clark S.C. et al. Interleukin–6 enhancement of interleukin–3 dependent proliferation of multipotential hemopoietic progenitors. Proc. Natl. Acad. Sci. USA. 1987; 84: 9035–9039.Ikebuchi K., Wong G.G., Clark S.C. et al. Interleukin–6 enhancement of interleukin–3 dependent proliferation of multipotential hemopoietic progenitors. Proc. Natl. Acad. Sci. USA. 1987; 84: 9035–9039.Kimura H., Ishibashi T., Uchida T. et al. Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. Eur. J. Immunol. 1990; 20: 1927–1931.Kimura H., Ishibashi T., Uchida T. et al. Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. Eur. J. Immunol. 1990; 20: 1927–1931.Tsigos C., Papankolaou D.A., Defensor R. et al. Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997; 66: 54–62.Tsigos C., Papankolaou D.A., Defensor R. et al. Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997; 66: 54–62.Heliovaara M.K., Teppo A.M., Karonen S.L. et al. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes. Metab. 2005; 7: 729–736.Heliovaara M.K., Teppo A.M., Karonen S.L. et al. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes. Metab. 2005; 7: 729–736.Cutolo M., Straub R.H. Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun. Rev. 2008; 7: 223–228.Cutolo M., Straub R.H. Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun. Rev. 2008; 7: 223–228.Nishimoto N. Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb. Exp. Pharmacol. 2008; 181: 151–160.Nishimoto N. Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb. Exp. Pharmacol. 2008; 181: 151–160.European Medicines Agency. Ro Actemra (tocilizumab): summary of product characteristics. URL: http://www.emea.europa.eu/humandoes/PDFs/EPAR/RoActemra/H-955-PI-en.pdf [accessed 2009 Mar 23].European Medicines Agency. Ro Actemra (tocilizumab): summary of product characteristics. URL: http://www.emea.europa.eu/humandoes/PDFs/EPAR/RoActemra/H-955-PI-en.pdf [accessed 2009 Mar 23].Chugai Pharmactutical Co. Actemra, a humanized antihuman IL–6 receptor monoclonal antibody obtained approval for indications of rheumatoid arthritis, polyarticular course juvenile idiopathic arthritis and systemic onset juvenile idiopathic arthritis [media release]. Available from URL: http://www.chugai-pharm.co.jp [accessed 2008 Sep 24].Chugai Pharmactutical Co. Actemra, a humanized antihuman IL–6 receptor monoclonal antibody obtained approval for indications of rheumatoid arthritis, polyarticular course juvenile idiopathic arthritis and systemic onset juvenile idiopathic arthritis [media release]. Available from URL: http://www.chugai-pharm.co.jp [accessed 2008 Sep 24].Imagawa T., Ozawa R., Miyamae T. et al. Efficacy and safety in 48-week treatment of tocilizumab in children with polyarticular course JIA with polyarticular or olygoarticular onset. Ann. Rheum. Dis. 2007; 66 (Suppl. II): 550.Imagawa T., Ozawa R., Miyamae T. et al. Efficacy and safety in 48-week treatment of tocilizumab in children with polyarticular course JIA with polyarticular or olygoarticular onset. Ann. Rheum. Dis. 2007; 66 (Suppl. II): 550.Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic onset juvenile idiopathic arthritis [SAT0536]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 715.Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic onset juvenile idiopathic arthritis [SAT0536]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 715.Inaba Y., Aoki C., Ozawa R. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [SAT0555]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 720.Inaba Y., Aoki C., Ozawa R. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [SAT0555]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 720.Yokota S., Imagawa T., Mori M. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 998–1006.Yokota S., Imagawa T., Mori M. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 998–1006.Yokota S., Miyamae T., Imagawa T. et al. Therapeutic efficacy of humanized recombinant anti–interleukin–6 receptor antibody in children with systemic onset juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52: 818-825.Yokota S., Miyamae T., Imagawa T. et al. Therapeutic efficacy of humanized recombinant anti–interleukin–6 receptor antibody in children with systemic onset juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52: 818-825.Aoki C., Inaba Y., Ozawa R. Effects of tocilizumab on radiological findings in polyarticular juvenile idiopathic arthritis [OP-0145]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 118.Aoki C., Inaba Y., Ozawa R. Effects of tocilizumab on radiological findings in polyarticular juvenile idiopathic arthritis [OP-0145]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 118.Quartier P., Maire D., Souabni L. Efficacy and safety of tocilizumab in systemic onset juvenile idiopathic arthritis in french centers [FRI0462]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 506.Quartier P., Maire D., Souabni L. Efficacy and safety of tocilizumab in systemic onset juvenile idiopathic arthritis in french centers [FRI0462]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 506.Kaneko U., Imagawa T., Kishi T. Discrepancy between progression of joint damage and improvement of systemic inflammation in patients with systemic-onset juvenile idiopathic arthritis treated with tocilizumab [SAT0548]. Ann. Rheum. Dis. 2009; 68 (Suppl.3): 719.Kaneko U., Imagawa T., Kishi T. Discrepancy between progression of joint damage and improvement of systemic inflammation in patients with systemic-onset juvenile idiopathic arthritis treated with tocilizumab [SAT0548]. Ann. Rheum. Dis. 2009; 68 (Suppl.3): 719.Giannini E.H., Ruperto N., Ravelli A. et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997; 40: 1202–1209.Giannini E.H., Ruperto N., Ravelli A. et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997; 40: 1202–1209.Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 715.Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 715.
The authors declare that there are no conflicts of interest present.